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ABSTRACT
Background. Radical gastrectomy is the cornerstone of
the treatment of locally advanced gastric cancer. This study
was designed to evaluate factors associated with a tumor-
positive resection margin after gastrectomy and to evaluate
the influence of hospital volume.
Methods. In this Dutch cohort study, patients with junc-
tional or gastric cancer who underwent curative
gastrectomy between 2011 and 2017 were included. The
primary outcome was incomplete tumor removal after the
operation defined as the microscopic presence of tumor
cells at the resection margin. The association of patient and
disease characteristics with incomplete tumor removal was
tested with multivariable regression analysis. The associ-
ation of annual hospital volume with incomplete tumor
removal was tested and adjusted for the patient- and dis-
ease characteristics.
Results. In total, 2799 patients were included. Incomplete
tumor removal was seen in 265 (9.5%) patients. Factors
associated with incomplete tumor removal were: tumor
located in the entire stomach (odds ratio (OR) [95%
confidence interval (CI): 3.38 [1.91–5.96] reference: gas-
troesophageal junction), cT3, cT4, cTx (1.75 [1.20–2.56],
2.63 [1.47–4.70], 1.60 [1.03–2.48], reference: cT0-2), pN?
(2.73 [1.96–3.80], reference: pN-), and diffuse and
unknown histological subtype (3.15 [2.14–4.46] and 2.05
[1.34–3.13], reference: intestinal). Unknown differentiation
grade was associated with complete tumor removal (0.50
[0.30–0.83], reference: poor/undifferentiated). Compared
with a hospital volume of\ 20 resections/year, 20–39, and
[ 39 resections were associated with lower probability for
incomplete tumor removal (OR 0.56 [0.42–0.76] and 0.34
[0.18–0.64]).
Conclusions. Tumor location, cT, pN, histological sub-
type, and tumor differentiation are associated with
incomplete tumor removal. The association of incomplete
tumor removal with an annual hospital volume of \ 20
resections may underline the need for further centralization
of gastric cancer care in the Netherlands.
A radical gastrectomy is one of the most important
predictors of survival in patients with gastric cancer.1 An
nonradical resection, i.e., gastrectomy with a tumor-posi-
tive resection margin (incomplete tumor removal), is seen
in approximately 1.8–8.4% of patients.2 In the Netherlands,
the percentage of incomplete tumor removal is used as one
of the quality indicators of gastrectomies. Between 2011
and 2016, of all gastrectomies for gastric cancer with
curative intent, in 9–13% the tumors were incompletely
removed.3 This number corresponds with other European
outcome registries.4,5 The British National Oesophago-
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Gastric Cancer Audit (NOGCA) reported that up to 29% of
the gastrectomies performed in individual hospitals had
tumor-positive margins.5 In the Swedish Register for
Esophageal and Gastric Cancer (NREV), the percentage of
incomplete tumor removal/unknown resection status was
17%.4
Gastric cancer surgery might involve tumor-positive
margins on the distal side (duodenum), proximal (gastric
remnant or esophagus), or circumferential. With the current
literature, it is unknown which side is most involved. The
Dutch national guideline, nevertheless, recommends a
proximal and distal resection margin of 60 mm.6
Awareness of increased risk for incomplete tumor
removal may prevent this undesirable outcome. However,
data on factors associated with incomplete tumor removal,
including preoperative risk assessment models, are scarce.
So far, retrospective studies have reported on cohorts from
single centers, and only few patients were included.2,7
Also, surgical expertise and quality assurance may play an
important role. Because individual surgical volume data
are difficult to retrieve, annual hospital volume is a widely
accepted proxy for surgical experience. For complex sur-
gery, including upper gastrointestinal surgery, there is
evidence that higher hospital volume and individual sur-
geon volume are associated with improved surgical quality
and outcome.8–11 However, the relation between hospital
volume and incomplete tumor removal has never been
investigated.
This study was designed to evaluate the factors associ-
ated with incomplete tumor removal in a Dutch cohort.
Furthermore, we sought the association between hospital
volume and incomplete tumor removal.
METHODS
Study Design
Patient data were retrieved from the Dutch Upper Gas-
trointestinal Cancer Audit. This surgical audit was initiated
in 2011. Hospitals are mandated to register all patients with
esophageal or gastric cancer undergoing surgery with
curative intent. The DUCA provides insight into the quality
of care by reporting validated process and outcome
parameters, defined as ‘‘quality indicators.’’
Because the radicality of an operation is used as one of
the quality indicators, the resection status (R0, R1, R2, not
applicable, or unknown), as well as the site of the resection
margin (proximal, distal, circumferential) in millimeters is
registered. For the reporting of the pathological examina-
tion of esophageal and gastric cancer, a standardized report
is used.12 For this study, data on pathology of the resection
specimen, patient, tumor, and treatment characteristics
were used. Validation of completeness and accuracy of
data registration in the DUCA dataset has been per-
formed.13 Patient- and hospital identity is anonymous in
this database. The study protocol was approved by the
DUCA scientific committee.
Patient Selection
Included were all patients with gastric cancer or cancer
of the esophagogastric junction (Siewert type I–III) who
underwent gastrectomy between 2011 and 2017 defined as
curative by the surgeon at the end of the operation.14
Patients were excluded if the resection status or essential
elements of the registration were unknown including date
of birth, survival status at 30 days after surgery or date of
discharge (in case of a hospital stay of[ 30 days).
Outcomes
The primary outcome was complete tumor removal as
documented by the pathologist based on examination of the
resection specimen. The definition of the College of
American Pathologists is used in the DUCA to define the
completeness of the tumor removal.15 Removal of the
tumor is considered complete (R0) if no microscopical
tumor cells are visible in the margin and incomplete (R1 or
R2) if microscopically or macroscopically tumor cells are
visible in the margin. (Patients whom the surgeon defined
the resection as complete and curative at the end of the
operation, but where the pathological examination showed
an R2 resection, were included, because this study focuses
on the surgeon’s estimation of the resection margins.)
Statistical Analysis
To compare patient and tumor characteristics between
the groups with an R0 and R1/R2 resection, the v2 test was
used. Univariable and multivariable logistic regression
analyses were performed to identify factors associated with
incomplete tumor removal. Factors with a P value\ 0.10
in univariable analyses or with clinical relevance were
included in the multivariable analyses. To test whether the
explanatory variables are useful in predicting the outcome,
the Nagelkerke R2 and an area under the receiver operating
characteristic curve (ROC) was used. By expert opinion,
possible factors for the preoperative associated risk model
were selected. At the selection of factors for this model, it
was decided to choose only patient and tumor character-
istics. Treatment characteristics, such as neo-adjuvant
chemotherapy and surgical approach, were not selected.
Because this could potentially lead to bias, these factors
were analysed with descriptive statistics. The factors’ age,
Charlson comorbidity score, American Society of
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Anesthesiologists (ASA) score, tumor location, TNM
stage, histological subtype, differentiation grade, and year
of surgery were used.16 To determine factors that can be
used preoperatively to identify patients who are at risk for
incomplete tumor removal, the clinical TNM category was
preferred for this analysis. However, for N-status of the
tumor it was chosen to use pN-stage. The first reason was
because an unknown clinical N-stage (cNx) was registered
in 13% of patients.17 Also, cN-stage and pN-stage do often
not correspond, and pN-stage is more reliable.
To test the association of annual hospital volume with
the resection status, logistic regression models were used
with and without adjustment for case-mix variety. Because
centralization has taken place in the Netherlands, analyses
were executed in the total cohort of 2011–2017 and strat-
ified for the most recent years 2014–2017. Between 2014
and 2017 hospital volumes were more constant. To address
possible confounding caused by differences in treatment
strategy between high- and low-volume hospitals, stratified
analyses for patients treated with or without neo-adjuvant
therapy was performed.
The annual hospital volume in the year of surgery was
assigned to each patient. Because the minimum annual
hospital volume in the Netherlands is 20 resections per year
and to draw clinically relevant conclusions, subsequently,
the volume was grouped into three groups: \ 20, 20–39,
and C 40 resections per year. Missing items were analyzed
in a separate group if exceeding 5%.
For all analyses, statistical significance was defined as
P\ 0.05. All analyses were performed with SPSS version
24 (IBM, Armonk, NY).
RESULTS
A total of 2799 patients had undergone a curative gas-
trectomy according to the surgeon at the end of the
operation and met the inclusion criteria (Fig. 1). The
majority of patients were male (63%), and the median age
Patients with an gastrectomy because of 
gastric cancer or cancer of the gastro- 
esophageal junction between 2011-2017 
registered in the DUCA
n=3104 Patients excluded because:
No curative intent:
Palliative n=92
Prophylactic n=14
Unknown intent n=18Curative intent of resection
n= 2980
Curative resection
n= 2894
n=2861
Patients excluded because:
No curative resection:
No resection n=6
Palliative resection n=74
Profylactic n=4
Unknown n=2
Patients excluded because:
Survival status (30-day) unknown n=29
Date of birth unknown n=4
Complete resection: n=2534 (89%) 
Incomplete resection: n=261 (9.2%) 
N.a.: n=8 (0.3%)
Unknown: n=16 (0.6%)
Missing: n=38 (1.3%)
Patients included: n=2799
Complete resection: n=2534 (91%)
Incomplete resection: n=265 (9.4%)
FIG. 1 Flowchart inclusion
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TABLE 1 Patient and tumor characteristics
Patient characteristics Total Complete tumor removal Incomplete tumor removal P value
n = 2799 n = 2534 (90.5%) n = 265 (9.5%)
n % n % n %
Gender 0.044
Man 1754 63 1603 63 151 57
Women 1045 37 931 37 114 43
Age (in groups) 0.142
\ 65 years 888 32 791 31 97 37
65–74 years 959 34 880 35 79 30
[ 75 years 952 34 863 34 89 34
Charlson score 0.119
0 1243 44 1121 44 122 46
1 634 23 587 23 47 18
2? 922 33 826 33 96 36
ASA score 0.17
I–II 1942 70 1768 70 174 66
III? 838 30 749 30 89 34
Unknown
Location of tumor \ 0.001
Esophageal-gastric junction/fundus 313 12 286 12 27 11
Corpus 833 31 775 31 58 23
Antrum/pylorus 1330 49 1214 49 116 45
Entire stomach 141 5 94 4 47 18
Pouch/anastomosis 109 4 99 4 10 4
Unknown 0 0 0 0 0 0
Clinical tumor category \ 0.001
cT0-2 825 30 781 31 44 17
cT3 1177 43 1041 42 136 52
cT4 152 6 128 5 24 9
cTx 602 22 542 22 60 23
Missing 0 0 0 0 0 0
Clinical node category 0.007
cN0 1433 52 1319 53 114 43
cN? 1038 38 925 37 113 43
cNx 288 10 251 10 37 14
Missing 0 0 0 0 0 0
Clinical metastases category 0.043
cM-0 2618 94 2375 94 243 92
cM? 44 2 35 1 9 3
cMx 137 5 124 5 13 5
Tumor histology 0.092
Adenocarcinoma 2633 95 2379 95 254 97
Squamous carcinoma 5 0 5 0 0 0
Other 133 5 127 5 6 2
Not applicable 3 0 2 0 1 0
Unknown 0 0 0 0 0 0
Histological subtype \ 0.001
Intestinal adenocarcinoma 1149 41 1097 43 52 20
Diffuse adenocarcinoma 823 29 676 27 147 56
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was 70 years [interquartile range: 62–77]. In 265 patients
(9.5%), the tumor was not completely removed. Patient and
tumor characteristics according to resection status are
shown in Table 1.
Tumor location, histological subtype, and differentiation
grade were statistically significant different between
patient with complete or incomplete tumor removal. Clin-
ical and pathological T-, N- and M-stage was more
advanced in patients with incomplete tumor removal.
Risk Factors for Incomplete Tumor Removal
A tumor located in the entire stomach (versus gastroe-
sophageal junction/fundus), higher cT-categories (cT3, cT4
and cTx category versus cT0-2), a pN?-category and pNx-
category (versus pN-), and diffuse or unknown type ade-
nocarcinoma (versus intestinal type) were associated with
incomplete tumor removal (Table 2). Unknown differen-
tiation grade was associated with a complete tumor
removal (compared with poor differentiation grade/undif-
ferentiated). The area under the ROC of the multivariate
model was 0.76.
TABLE 1 continued
Patient characteristics Total Complete tumor removal Incomplete tumor removal P value
n = 2799 n = 2534 (90.5%) n = 265 (9.5%)
n % n % n %
Mixed type 164 6 153 6 11 4
Unknown 663 24 608 24 55 21
Differentiation grade \ 0.001
Well/moderate 881 32 835 33 46 17
Poor/undifferentiated 1471 53 1273 50 198 75
Not available 93 3 91 4 2 1
Unknown 354 13 335 13 19 7
Pathological tumor stage \ 0.001
pT0-2 1030 37 1010 40 20 8
pT3 1094 40 977 39 117 45
pT4 614 22 490 20 124 47
pTx 32 1 30 1 2 1
Missing 0 0 0 0 0 0
Pathological node stage \ 0.001
pN0 1254 45 1198 48 56 21
pN? 1481 53 1277 51 204 78
pNx 36 1 33 1 3 1
Missing 0 0 0 0 0 0
Pathological metastases stage \ 0.001
pM0 2490 89 2272 90 218 82
pM1 118 4 89 4 29 11
pMx 54 2 47 2 7 3
Not applicable 137 5 126 5 11 4
cT versus pT staging 0.019
Correct estimated 549 20 509 20 40 15
Underestimated T stage 256 9 218 9 38 14
Overestimated T stage 72 3 68 3 4 2
cTx 283 10 256 10 27 10
pTx 21 1 20 1 1 0
cT or pT missing 0 0 0 0 0 0
Not applicable (neoadjuvant therapy) 1585 57 1431 57 154 58
ASA American Society of Anesthesiologists
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TABLE 2 Probability for incomplete tumor removal, results of uni- and multi-variable analyses
Probability for incomplete tumor removal Univariable analysis Multivariable analysis
Variables n OR [95% CI] P value n OR [95% CI] P value
Total 2799 2671
Age (year) 0.143
0–64 888 1
65–74 959 0.73 [0.54–1] 0.050
75? 952 0.84 [0.62–1.14] 0.263
Charlson score 0.121
0 1243 1
1 634 0.74 [0.52–1.05] 0.087
2? 922 1.07 [0.81–1.42] 0.648
ASA score 0.170
I/II 1942 1
III? 838 1.21 [0.92–1.58]
Tumor location \ 0.001 \ 0.001
GEJ/Fundus 313 1 304 1
Corpus 833 0.79 [0.49–1.28] 0.339 813 0.70 [0.43–1.16] 0.167
Antrum/pylorus 1330 1.01 [0.65–1.57] 0.957 1308 0.95 [0.60–1.50] 0.828
Entire stomach 141 5.30 [3.13–8.98] \ 0.001 138 3.38 [1.91–5.96] \ 0.001
Pouch/residual stomach 109 5.30 [3.13–8.98] 0.862 108 1.14 [0.51–2.57] 0.749
Clinical tumor category \ 0.001 0.005
cT0-2 825 1 808 1
cT3 1177 2.32 [1.63–3.30] \ 0.001 1137 1.75 [1.20–2.56] 0.004
cT4 152 3.33 [1.96–5.66] \ 0.001 146 2.63 [1.47–4.70] 0.001
cTx 602 1.97 [1.31–2.94] 0.001 580 1.60 [1.03–2.48] 0.036
Pathological node category \ 0.001 \ 0.001
pN- 1254 1 1207 1
pN? 1481 3.42 [2.52–4.64] \ 0.001 1433 2.73 [1.96–3.80] \ 0.001
pNx 36 1.95 [0.58–6.53] 0.282 31 3.17 [0.86–11.61] 0.082
Clinical metastases category 0.053 0.984
cM0 2618 1 2517 1
cM1 44 2.51 [1.19–5.29] 0.015 43 1.08 [0.46–2.51] 0.867
cMx 137 1.03 [0.57–1.84] 0.935 111 1.02 [0.53–1.99] 0.948
Histological subtype \ 0.001 \ 0.001
Intestinal adenocarcinoma 1149 1 1112 1
Diffuse adenocarcinoma 823 4.59 [3.30–6.38] \ 0.001 797 3.15 [2.14–4.64] \ 0.001
Mixed type 164 1.52 [0.77–2.97] 0.224 160 1.02 [0.50–2.06] 0.963
Unknown 663 1.91 [1.29–2.82] 0.001 602 2.05 [1.34–3.13] 0.001
Differentiation grade \ 0.001 0.017
Well/moderate 881 0.35 [0.25–0.49] 839 0.72 [0.48–1.06]
Poor/undifferentiated 1471 1 \ 0.001 1417 1 0.096
Not applicable 93 0.14 [0.04–0.58] 0.006 89 0.33 [0.08–1.38] 0.129
Unknown 354 0.37 [0.22–0.59] \ 0.001 326 0.50 [0.30–0.83] 0.008
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Hospital Volume
In Fig. 2, the centralization of gastric surgery in the
Netherlands is shown. Compared with 2011, the hospital
volumes were higher in 2017, and the number of hospitals
performing gastric surgery decreased.
In all logistic regression models, annual hospital volume
of \ 20 was associated with a higher percentage of
incomplete tumor removal compared to annual hospital
volumes of 20–39 and C 40 resections per year (Table 3).
There was no statistically significant difference between
20–39 and C 40 resections per year. In a sensitivity anal-
ysis including data from the period 2014–2017, similar
results were found (data not shown). In stratified analyses
according to neo-adjuvant therapy, similar results were
found. Patients not treated with neo-adjuvant therapy, with
a volume of\ 20 resections/year had a higher probability
for incomplete tumor resection compared to 20–39 resec-
tions/year and 40 or more resections/year (OR: 0.60
[0.37–0.98] and 0.19 [0.05–0.69], respectively). In patients
treated with neo-adjuvant therapy, the probability for
incomplete tumor resection also was higher for low hos-
pital volume (\ 20 resections/year) compared with
20–39 resections/year (OR: 0.65 [0.43–0.98]) and for 40 or
more resections/year (OR 0.50 [0.23–1.09]).
Site of Tumor-Positive Margin
In 175 of 265 patients with incomplete tumor removal,
the site of the tumor-positive resection margin was reported
in the DUCA (Supplementary Table 1). When the resection
of the tumor was incomplete, the proximal resection mar-
gin was mostly involved in patients with proximal gastric
cancer (junctional/fundus 86% and corpus 80%). Gastrec-
tomy for distal tumors (antrum/pylorus) was most often
incomplete at the distal margin (68%). When the tumor
was located in the entire stomach, the resection was
incomplete at the distal margin in 17%, the proximal
margin in 42%, and involvement of both margins was seen
in 42% of patients (Supplementary Table 2).
DISCUSSION
This Dutch cohort study shows that patients with
advanced gastric cancers (i.e., involving the entire stom-
ach, advanced TNM-stage, and diffuse-type gastric cancer)
are at risk for incomplete tumor removal. Furthermore, low
annual hospital volume (\ 20 resections per year) also is
associated with a higher risk for incomplete tumor removal
than middle and high-volume hospitals. The present study
is the first population-based study reporting patient-related
and tumor-related factors associated with incomplete tumor
removal for gastric cancer. The risk factors that were
identified in this national cohort study are similar to earlier
studies: Songun et al.17 reported the association between
incomplete tumor removal with tumor location and size of
the tumor. Other studies reported the association between
incomplete tumor removal and diffuse type carcinoma.18,19
The risk factors identified in the present study appear to be
related to more advanced stomach cancer, and this in itself
might be a risk factor for an incomplete tumor removal.
In addition to patient and tumor factors, Bissolati et al.
studied the association between the distance from the
tumor to the margin of resection and incomplete tumor
removal. They showed that resection margins of\ 20 mm
in T1 tumors resection and resection margins of\ 30 mm
in and T2-4 tumors were associated with incomplete tumor
removal.7 In the present study, the association of resection
margin with incomplete tumor removal could not be
assessed. Based on the study by Bissolati et al., it could be
argued that an extra wide resection margin may prevent
incomplete tumor removal. The Dutch guideline recom-
mends a minimum resection margin of 60 mm.6 The
TABLE 2 continued
Probability for incomplete tumor removal Univariable analysis Multivariable analysis
Variables n OR [95% CI] P value n OR [95% CI] P value
Year of resection 0.562
2011 250 1
2012 319 0.71 [0.42–1.20] 0.199
2013 448 0.71 [0.43–1.15] 0.160
2014 498 0.78 [0.49–1.25] 0.294
2015 419 0.66 [0.40–1.09] 0.104
2016 475 0.64 [0.39–1.05] 0.078
2017 390 0.61 [0.36–1.02] 0.061
ASA American Society of Anesthesiologists
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German guideline recommends a resection margin of
50 mm for intestinal type and 80 mm for diffuse-type
gastric cancer.20
Choosing an appropriate surgical margin can be chal-
lenging. The margin should be wide enough to prevent
incomplete tumor removal but at the same time a techni-
cally feasible and reliable reconstruction should be created.
To achieve a safe proximal resection margin for middle
gastric tumors, a total gastrectomy may be indicated.
Although postoperative mortality and 5-year survival after
total and subtotal gastrectomy is comparably, a subtotal
gastrectomy is associated with less nutritional side effects
and a better quality of life.21
For proximal gastric tumors that invade the esophagus, a
more technically challenging anastomosis in the lower
mediastinum or a total gastrectomy with subtotal
esophagectomy and colonic interposition may be indicated.
This procedures have a higher risk for anastomotic leakage
or other postoperative complications.22,23
Bissolati et al. also showed that there was an association
between incomplete tumor removal at the esophagogastric
junction. However, the surgeon may be confronted intra-
operatively with a difficult decision as how to deal with
suspicious extension of the tumor beyond what was
anticipated. Proximal gastric cancers may invade the
esophagus and the proximal resection margin is at risk.
50 100%
45 90%
40 80%
35 70%
30 60%
25 50%
20 40%
15 30%
10 20%
0
5 10%
0%
2011 2012 2013 2014 2015 2016 2017 2011 2012 2013 2014 2015 2016 2017
Number of hospitals Percentage of patients treated in hospitals with different volumes
0-19 resections/hospital 20-39 resections/hospital ≥40 resections/hospital
FIG. 2 Centralization gastric cancer surgery
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In the present study, tumor location was not associated
with incomplete tumor removal. Distal gastric cancers may
invade the duodenum and a Whipple’s operation for
patients who can tolerate this should be considered. In the
Netherlands, the foundation for oncological cooperation
(SONCOS) recommends that gastric and esophageal
resections should be performed in the same hospital.24
However, there are no recommendations regarding the
combination of gastric and hepatobiliary surgery.25
Therefore, when it is anticipated that the proximal margin
at the esophagus or the duodenum is at risk, it is probably
advisable to refer patients to hospitals where esophageal
and/or hepatobiliary surgery is performed.
To facilitate a radical resection without unnecessarily
wide resection margins, intraoperative frozen-section
analysis could be used. However, this technique is time-
consuming, and the clinical value can be dubious since
results can be false negative.26,27 Squires et al. evaluated
outcomes of patients with gastric cancer with a positive
intraoperative proximal frozen section converted to an R0
resection in the same procedure. The local recurrence was
significantly lower in the converted-to-R0 group than in
patients with a positive final frozen section. This study
showed that overall survival and progression-free survival
was not improved.28 If time is a concern of hospitals, a
frozen section could be considered to achieve a R0 resec-
tion in high-risk patients as identified in this study rather
than in all patients.
Additionally, intraoperative endoscopic ultrasonography
may help to determine the extent of infiltration in the
esophagus or duodenum.29 Kawakatsu et al. described the
combination of preoperative placement of marking clips
TABLE 3 Multiple regression models to test the association of hospital volume with incomplete tumor removal
Probability for incomplete tumor removal based on patient and tumor
characteristics
2011–2017
n OR 95% CI P value Nagelkerke
R2
ROC
Total 2671 0.17 0.76
Patient and tumor factors added to the model: location tumor, cT
category, pN stage, cM category, histological subtype,
differentiation grade
Hospital volume 0.001
Not adjusted \ 20
resections/
year
1388 1
20–39
resections/
year
1155 0.68 [0.52–0.89] 0.004
40 or more
resections/
year
256 0.41 [0.23–0.74] 0.003
Hospital volume \ 0.001
Adjusted for: location tumor, cT category, pN stage, cM category,
histological subtype, differentiation grade
\ 20
resections/
year
1308 1
20–39
resections/
year
1134 0.56 [0.42–0.76] \ 0.001
40 or more
resections/
year
229 0.34 [0.18–0.64] 0.001
Hospital volume (other reference) \ 0.001
Adjusted for: location tumor, cT category, pN stage, cM category,
histological subtype, differentiation grade
\ 20
resections/
year
1308 2.95 [1.57–5.55] 0.001
20–39
resections/
year
1134 1.66 [0.88–3.13] 0.120
40 or more
resections/
year
229 1
2230 L. R. van der Werf et al.
and intraoperative endoscopy as being helpful to determine
a surgical margin in patients who undergo laparoscopic
gastrectomy. However, this is the only study that describes
the systematical use of endoscopy during gastrectomy.
Further studies are needed to evaluate the benefits of this
technique.
Besides tumor-related factors, the surgeon’s experience
with esophageal and gastric cancer surgery and the number
of operations per year performed (hospital volume) may be
important to reduce the number of incomplete resections.
In the present study, a hospital volume of \ 20 gastric
resections per year was associated with a higher chance of
incomplete tumor removal compared with 20–50 and[ 50
resections per year. In the past, the association between
hospital volume and postoperative morbidity/mortality and
overall survival has been studied.8–10,30–33 For overall
survival, conflicting results were published. However, for
postoperative morbidity and mortality, several studies
reported improved outcomes in high-volume centers. More
recently, low hospital volume (\ 25 resections per year)
was associated with fewer retrieved lymph nodes.34
Between 2012 and 2014, the Association of Surgeons of
the Netherlands introduced volume standards for complex
surgery. In particular for gastric surgery, a minimum vol-
ume of 10 gastric cancer resections in 2012, and from 2013
onwards a minimum of 20 resections per year was required.
Currently, some Dutch hospitals have not met this standard
yet, and centralization in gastric surgery is still ongoing
(Fig. 2). It may be possible that hospitals with a relatively
low number of patients with gastric cancer use more liberal
criteria to select patients for gastrectomy to comply with
the minimum required target. This may result in worse
outcomes, e.g., higher rates of incomplete tumor removal.
At present, we are performing a more in-depth examination
in several hospitals to identify if organizational, human, or
technical factors contribute to unfavorable outcomes after
gastrectomy. Nevertheless, the current study endorses the
need for centralization of gastric cancer surgery. Another
strategy could involve discussing complex patients in a
multicenter, multidisciplinary team.35
In the case of postoperative determination of tumor-
positive resection margins, some studies describe that
adjuvant chemoradiotherapy is associated with improved
survival, especially for patients who had no neoadjuvant
therapy.36–38 Another option that may benefit is to perform
a reoperation with resection of the tumor-positive resection
margins.39,40 The largest cohort of reoperations was 122
patients, and a reoperation was successfully performed in
41% of these patients. The authors of the study describe a
survival benefit especially for stage N2 or lower tumors.41
However, evidence for an optimal treatment after an
incomplete tumor removal is based on nonrandomized
studies with small patient groups.
The main strength of this study is the nationwide cov-
erage of the dataset allowing national performance to be
assessed. Outcomes of studies using population-based data
reflect daily clinical practice. Prospective (randomized)
trials are usually conducted under strict quality control and
only with selected patients and thus may not reflect the real
world. A national registry might do reflect the real world.
However, a database from a national registry also may
have its disadvantages; the accuracy and completeness of
data may be questioned. Nevertheless, we believe that the
DUCA database is accurate to answer our research ques-
tion. The case ascertainment of the DUCA database is
estimated at 97.8%, and the resection status is reported
with high completeness (1.6% missing; Fig. 1).13 Because
in the Netherlands, the information regarding resection
margins must be reported according to a standardized
pathology report. We assume that the accuracy of the
registered resection status also is high.12
Another limitation is the retrospective nature of this
study. In this study, we could not evaluate the influence of
treatment-related factors on resection status, such as neo-
adjuvant chemotherapy and the surgical approach. The
reason for this is that bias in the selection of patients for
specific treatments may have occurred (treatment by indi-
cation bias). Therefore, this study could not evaluate much-
discussed, treatment-related factors, such as the approach
of surgery. However, recently, a study with data of the
DUCA compared minimally invasive gastrectomy with
open gastrectomy in a propensity-matched cohort. This
study showed no differences in resection status between the
two groups (R0 in 88% vs. 85%, P = 0.189).42 Another
potential treatment-related factor that could not be evalu-
ated in this study is inadequate diagnostic staging. From
the present dataset, it was not possible to compare the
diagnostic workup between patients who underwent a
complete and incomplete tumor removal, because both
patient identity and hospital identity are anonymous.
Finally, data on survival were not available. Therefore,
evaluation of the (independent) association of complete
resection with survival was not possible. A gastrectomy
with tumor-positive margins may reflect an aggressive
biology of the tumor and as a consequence have a poor
prognosis. Even after gastrectomy with negative resection
margins, large, poorly differentiated tumors will likely
spread beyond the surgical field, and surgery cannot cure
these patients. Future studies may be needed to evaluate the
independent association of incomplete resections with
survival.
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